Sermorelin + AOD-9604 Stack: Complete Protocol

How Each Peptide Works: Two Different Mechanisms

Sermorelin and AOD-9604 act through entirely separate biological pathways. That separation is the entire rationale for combining them. One compound amplifies growth hormone output; the other modulates fat-cell metabolism directly, leaving the GH axis largely untouched.

Sermorelin: Pituitary Stimulation Via GHRH Receptor

Sermorelin acetate is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) comprising the first 29 amino acids of the native 44-amino-acid peptide. It binds the GHRH receptor on somatotroph cells of the anterior pituitary, triggering a cAMP cascade that results in pulsatile growth hormone secretion [1].

Because sermorelin works through the native hypothalamic-pituitary axis, it preserves the physiological feedback loops that prevent excess GH accumulation. Somatostatin release still provides a ceiling. This makes the GH response more physiological than direct recombinant HGH injection, where supraphysiologic peaks can occur.

Circulating GH then stimulates hepatic IGF-1 production. IGF-1 mediates most of the anabolic and lipolytic downstream effects attributed to GH, including lean mass support and visceral fat reduction [2].

AOD-9604: Fat-Cell Targeting Without IGF-1 Elevation

AOD-9604 is the C-terminal fragment spanning residues 176-191 of human growth hormone. Early research from Metabolic Pharmaceuticals (Australia) showed that this fragment retains the lipolytic properties of full-length GH but does not bind the GH receptor in a way that triggers IGF-1 production or mitogenic signaling [3].

The proposed mechanism involves beta-3 adrenergic receptor stimulation in adipocytes, promoting lipolysis, and a second pathway that appears to inhibit lipogenesis. A 12-week study in obese mice demonstrated statistically significant reductions in body fat compared to placebo, without the glucose-handling problems seen with full-length GH administration [4].

Metabolic Pharmaceuticals advanced AOD-9604 to Phase II clinical trials in obese adult humans. The CLINICAL-II data (Clinicaltrials.gov NCT identifier, Sponsor: Metabolic Pharmaceuticals) showed dose-dependent fat mass reductions, though the effect size at the 1 mg oral dose was modest and the program was ultimately not advanced to Phase III [5].

Because AOD-9604 does not meaningfully raise IGF-1 at doses used clinically, it is sometimes preferred by patients or practitioners who want lipolytic support without additional IGF-1 exposure.

Rationale for Stacking Sermorelin With AOD-9604

The logic behind combining these two compounds rests on complementary, not redundant, mechanisms.

Dual-Pathway Coverage for Body Composition

Sermorelin raises GH and IGF-1, which promotes lean mass preservation, improves sleep architecture, and supports metabolic rate [2]. AOD-9604 acts directly at the adipocyte through a pathway that does not depend on GH receptor occupancy. Theoretically, pairing them addresses body composition through both an anabolic/systemic GH-axis pathway and a direct lipolytic pathway simultaneously.

No human RCT has tested this exact combination. The rationale is constructed from individual mechanistic data for each peptide and practitioner-reported clinical outcomes. Readers should weigh that evidence gap carefully before beginning any protocol.

Why IGF-1 Non-Elevation From AOD-9604 Matters

Chronically elevated IGF-1 has been associated with increased proliferation risk in some cancer cell lines, a concern that has shaped prescribing caution around exogenous HGH [6]. Because AOD-9604 does not drive IGF-1 upward at standard doses, stacking it with a comparatively lower dose of sermorelin (rather than a higher dose of sermorelin alone) may let a clinician achieve meaningful lipolytic effect while keeping total IGF-1 exposure lower than a high-dose-sermorelin-only approach. This is a theoretical benefit, not a proven risk reduction.

Pulsatility and Timing Compatibility

Sermorelin is typically dosed at night to align with the physiological nocturnal GH pulse, which normally peaks in the first hours of slow-wave sleep [7]. AOD-9604 is most often dosed in the fasted morning state or 30 minutes before exercise, when free fatty acids are being actively mobilized. These timing windows do not conflict, making co-administration logistically straightforward.

Complete Dosing Protocol

The following framework synthesizes published pharmacokinetic data for each compound with practitioner-reported dosing patterns. It has not been validated in a prospective clinical trial and should be reviewed by a licensed prescriber before implementation.

Sermorelin Dosing

Starting dose: 200 mcg subcutaneous injection, administered 30-60 minutes before sleep on an empty stomach (no food for at least 2 hours prior).

Titration: After 4 weeks, if GH and IGF-1 labs remain in the lower quartile of age-adjusted reference ranges and the compound is well-tolerated, the prescribing clinician may increase to 300 mcg nightly.

Maximum commonly used dose: 500 mcg nightly. Doses above this threshold have been used in published GHRH-deficiency research but are rarely necessary for general body-composition applications [1].

Injection site: Subcutaneous, rotating between the abdomen, lateral thigh, and outer upper arm. A 29-31 gauge, 5/16-inch needle is standard.

Frequency: Nightly, 5-7 days per week. Some protocols use 5 days on, 2 days off to limit pituitary desensitization, though direct evidence for desensitization at standard doses is limited.

AOD-9604 Dosing

Standard dose: 250-500 mcg subcutaneous injection once daily.

Timing: Fasted state, either first thing in the morning or 30 minutes before exercise. Food, especially carbohydrates, may blunt the lipolytic response by raising insulin, which directly inhibits adipose tissue lipolysis [8].

Frequency: Once daily, 5-7 days per week.

Oral vs. Subcutaneous: Oral AOD-9604 was studied in the Metabolic Pharmaceuticals trials at doses of 1 mg. Subcutaneous administration bypasses first-pass degradation and may require lower doses to achieve comparable plasma concentrations, though direct bioavailability comparison data in humans are limited.

Cycle Length and Periodization

A 12-week minimum cycle is generally accepted as the threshold at which clinically meaningful body-composition changes become measurable for GHRH-based protocols. Many clinicians run 16-24 weeks, citing the gradual nature of GH-axis optimization [9].

After a full cycle, a 4-8 week off period allows assessment of maintained benefits and avoids the theoretical risk of sustained pituitary receptor downregulation. Lab monitoring of IGF-1 guides restart timing.

Drug Interactions and Contraindications

Sermorelin is contraindicated in patients with active malignancy (because of the IGF-1 axis), untreated hypothyroidism (thyroid hormone is required for full GH bioactivity), and in pregnancy or active breastfeeding [10].

AOD-9604 does not have an FDA-approved prescribing label. Practitioners operating within compounding pharmacy frameworks typically apply the same contraindications used for full-length GH: active neoplasia, proliferative diabetic retinopathy, and severe obstructive sleep apnea.

Combining either peptide with exogenous insulin, sulfonylureas, or SGLT-2 inhibitors warrants careful glucose monitoring, as shifts in fat metabolism and GH axis activity can affect insulin sensitivity.

Lab Monitoring Schedule

Monitoring is not optional when using GH-axis peptides. It is what distinguishes clinical use from unguided self-experimentation.

Baseline Labs (Before Starting)

Order the following before the first injection:

• IGF-1 (age-adjusted reference range)
• Fasting glucose and HbA1c
• Fasting insulin (HOMA-IR calculation)
• Thyroid panel (TSH, free T4)
• Comprehensive metabolic panel
• Lipid panel
• PSA in males over 40

On-Cycle Labs (Week 6-8)

• IGF-1: target the upper third of the age-adjusted reference range, not above the range ceiling
• Fasting glucose: AOD-9604 should not worsen glucose handling; sermorelin at high doses can transiently raise fasting glucose through GH counter-regulatory effects [11]
• Symptom check: fluid retention, joint aching, carpal tunnel symptoms, or increased fatigue may indicate GH excess and warrant dose reduction

End-of-Cycle Labs (Week 12-16)

Repeat the full baseline panel. Body composition measurement via DEXA scan at baseline and end-of-cycle provides objective data beyond scale weight and is the preferred method in clinical trials assessing GH-secretagogue protocols [9].

Evidence Grading: What the Science Actually Shows

Being honest about evidence quality is not a limitation of this article. It is the responsible way to discuss compounds that are not FDA-approved for the indications being discussed.

Sermorelin: Level of Evidence

Sermorelin received FDA approval in 1997 under the brand name Geref for treatment of idiopathic GH deficiency in children [12]. That approval was later withdrawn for commercial reasons, not safety concerns. The mechanistic and pharmacokinetic database for sermorelin in adults is therefore more substantial than for most other peptides used in longevity or body-composition medicine.

A study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that GHRH analogue administration in GH-deficient adults produced significant increases in IGF-1 and lean mass over 6 months [2]. The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency in adults states: "We recommend using IGF-1 to assess the adequacy of GH replacement" [13], a principle that applies to sermorelin monitoring even in the off-label context.

AOD-9604: Level of Evidence

The highest-quality human data for AOD-9604 comes from the Metabolic Pharmaceuticals Phase IIb trial, which enrolled 300 obese adults and randomized them to oral AOD-9604 at doses from 1 mg to 54 mg daily versus placebo over 12 weeks. The 1 mg group achieved statistically significant fat mass reduction compared to placebo at 12 weeks (P<0.05), with no significant change in fasting insulin or IGF-1 [5]. Effect sizes were modest: approximately 1.3 kg more fat mass lost in the active arm vs. Placebo.

Animal data are more compelling in magnitude. A 1996 paper in Biochemical and Biophysical Research Communications reported that AOD-9604 reduced body weight in obese mice by 50% over 7 weeks when compared to saline controls [4]. The translation from rodent obesity models to humans is notoriously imprecise, and clinicians should not extrapolate those effect sizes directly.

The Combination: No RCT Data Exists

No published randomized controlled trial has tested sermorelin plus AOD-9604 together in humans. The evidence for their combination is built entirely from:

1. Individual mechanistic data for each compound
2. The theoretical complementarity of their pathways
3. Practitioner-reported outcomes in telehealth and compounding pharmacy settings (anecdotal, not peer-reviewed)

This evidence gap does not make the stack inherently dangerous. It does mean a patient cannot point to a trial proving the combination is more effective than either compound alone.

Side Effects and Safety Profile

Sermorelin Side Effects

Reported side effects from sermorelin at standard clinical doses include:

• Injection site reactions (redness, mild swelling): most common, typically resolve within 24 hours
• Headache: occurs in roughly 15-20% of new users and often resolves within the first 2 weeks [12]
• Flushing and transient nausea: less common, dose-dependent
• Water retention and joint discomfort at higher doses: consistent with mild GH excess

Serious adverse events at doses used for body composition are rare in published literature. Hypersensitivity reactions have been reported and are reason for immediate discontinuation.

AOD-9604 Side Effects

The Phase II human trial data reported a favorable safety profile at 1 mg oral dosing. The most common adverse events were gastrointestinal: nausea (8.3% active vs. 5.2% placebo) and mild headache [5]. At subcutaneous doses used in compounding pharmacy settings (250-500 mcg), the side-effect profile appears similar based on practitioner reports, though this population has not been studied in a formal safety trial.

AOD-9604 does not appear to cause the glucose intolerance seen with full-length HGH, which is one of the reasons it was initially developed as a potential obesity drug [3].

Special Populations

Patients with type 2 diabetes require more frequent glucose monitoring when starting GH-axis peptides. Hypothyroid patients should have TSH optimized before beginning sermorelin, since GH bioactivity depends on adequate thyroid hormone levels. Patients with a personal or first-degree family history of hormone-sensitive cancers should discuss risk with an oncologist before starting any IGF-1-elevating compound.

Practical Administration Guidance

Reconstitution (Lyophilized Vials)

Both peptides are commonly supplied as lyophilized powder requiring reconstitution with bacteriostatic water.

• Add bacteriostatic water slowly by injecting it down the side of the vial, not directly onto the powder cake.
• Gently swirl. Never shake; shaking can degrade the peptide bonds.
• Sermorelin is typically supplied at 3 mg or 6 mg per vial. Adding 3 mL bacteriostatic water to a 3 mg vial yields 1,000 mcg/mL; a 300 mcg dose then requires 0.3 mL (30 units on a 100-unit insulin syringe).
• AOD-9604 is commonly supplied at 5 mg per vial. Adding 2.5 mL bacteriostatic water yields 2,000 mcg/mL; a 500 mcg dose requires 0.25 mL.

Store reconstituted peptides refrigerated at 2-8 degrees Celsius. Discard unused reconstituted solution after 30 days or per the compounding pharmacy's labeled expiration.

Injection Technique

Clean the injection site with an alcohol swab and allow it to dry for 10 seconds. Pinch the skin lightly. Insert the needle at a 45-90 degree angle depending on subcutaneous tissue depth. Inject slowly. Remove the needle and apply gentle pressure without rubbing.

Rotate injection sites across the abdomen, thighs, and arms to prevent lipohypertrophy.

Who Is and Is Not a Candidate

A patient may be a reasonable candidate for clinician-supervised sermorelin if IGF-1 levels fall in the bottom third of the age-adjusted reference range, body composition goals include lean mass maintenance alongside fat reduction, and they have no contraindications listed above.

AOD-9604 stacking may be most relevant when a patient has a primary goal of fat mass reduction and wants to limit cumulative IGF-1 exposure relative to a higher-dose sermorelin-only approach.

Patients with active cancer, poorly controlled diabetes, untreated hypothyroidism, or a BMI <22 without clinical indication are generally not candidates for this stack.

The FDA has not approved either compound for body composition use. Both are available in the United States through licensed compounding pharmacies, subject to prescriber oversight and applicable state pharmacy board regulations. The FDA's 2023 guidance on compounded drugs [14] and the ongoing regulatory environment around compounded GLP-1 and peptide products underscores the importance of working with a licensed provider who documents medical necessity.